Duration of treatment as a risk factor for metabolic syndrome in patients with schizophrenia receiving antipsychotic medication
Other Title(s)
مدة العلاج كعامل خطورة لمتلازمة الأيض في مرضى الفصام الذين يتلقون مضادات الفصام
Joint Authors
Hasan, Haydi
Ahmad, Basmah
Fahmi, Majidah
Muhammad, Khalid Abd al-Muizz
Source
The Arab Journal of Psychiatry
Issue
Vol. 28, Issue 1 (31 May. 2017), pp.46-51, 6 p.
Publisher
The Arab Federation of Psychiatrists
Publication Date
2017-05-31
Country of Publication
Jordan
No. of Pages
6
Main Subjects
Abstract EN
ackground: Metabolic syndrome is a leading cause of morbidity and mortality in patients with schizophrenia.
The prevalence rate is double that of a non-psychiatric population.
Objective: The present study aimed to determine the duration of treatment as a risk factor for metabolic syndrome in patients with schizophrenia receiving antipsychotic medication.
Methods: Structured psychiatric interview was conducted using ICD-10 criteria, laboratory investigation (TG (triglycerides), HDL (high-density lipid), blood pressure, fasting blood glucose and metabolic syndrome based on the national cholesterol education program adult treatment panel three criteria.
Results: The present study showed that 52.9% did not fulfill the criteria for metabolic syndrome with 47.1% meeting the criteria.
The incidence of metabolic syndrome in those who received second-generation antipsychotics was 68.6% while metabolic syndrome in those who received first generation antipsychotics was 25.7%.
Conclusion: There was a statistically significant difference between the incidence of metabolic syndrome and duration of treatment in the two groups being studied.
American Psychological Association (APA)
Ahmad, Basmah& Fahmi, Majidah& Muhammad, Khalid Abd al-Muizz& Hasan, Haydi. 2017. Duration of treatment as a risk factor for metabolic syndrome in patients with schizophrenia receiving antipsychotic medication. The Arab Journal of Psychiatry،Vol. 28, no. 1, pp.46-51.
https://search.emarefa.net/detail/BIM-795127
Modern Language Association (MLA)
Ahmad, Basmah…[et al.]. Duration of treatment as a risk factor for metabolic syndrome in patients with schizophrenia receiving antipsychotic medication. The Arab Journal of Psychiatry Vol. 28, no. 1 (May. 2017), pp.46-51.
https://search.emarefa.net/detail/BIM-795127
American Medical Association (AMA)
Ahmad, Basmah& Fahmi, Majidah& Muhammad, Khalid Abd al-Muizz& Hasan, Haydi. Duration of treatment as a risk factor for metabolic syndrome in patients with schizophrenia receiving antipsychotic medication. The Arab Journal of Psychiatry. 2017. Vol. 28, no. 1, pp.46-51.
https://search.emarefa.net/detail/BIM-795127
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 50-51
Record ID
BIM-795127